1 Germline cancer gene expression quantitative trait loci influence local and global tumor

- 2 mutations
- 3 Yuxi Liu^{1,2,3}, Alexander Gusev³, Peter Kraft^{1,2,4,*}
- 4 1. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA,
- 5 02115, USA
- 6 2. Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of
- 7 Public Health, Boston, MA, 02115, USA
- 8 3. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical
- 9 School, Boston, MA, 02215, USA
- 10 4. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA,
- 11 02115, USA
- 12 * Corresponding author: Peter Kraft, PhD. Program in Genetic Epidemiology and Statistical
- 13 Genetics, Harvard T.H. Chan School of Public Health, 655 Huntington Avenue, Boston, MA,
- 14 02115. Email: <u>pkraft@hsph.harvard.edu</u>
- 15 **Running title:** Germline cancer gene eQTL influence tumor mutations
- 16 Keywords: germline variant, somatic mutation, cancer driver gene, TMB, gene expression
- 17 **Conflict of interest:** The authors declare no potential conflicts of interest.

18

19 Abstract

20	Somatic mutations drive cancer development and are relevant to patients' response to treatment.
21	Emerging evidence shows that variations in the somatic genome can be influenced by the
22	germline genetic background. However, the mechanisms underlying these germline-somatic
23	associations remain largely obscure. We hypothesized that germline variants can influence
24	somatic mutations in a nearby cancer gene ("local impact") or a set of recurrently mutated cancer
25	genes across the genome ("global impact") through their regulatory effect on gene expression.
26	We integrated tumor targeted sequencing from 12,413 patients across 11 cancer types in the
27	Dana-Farber Profile cohort with germline cancer gene expression quantitative trait loci (eQTL)
28	from the Genotype-Tissue Expression Project. We identified variants that upregulate ATM
29	expression which are also associated with a decreased risk of having somatic ATM mutations
30	across 8 cancer types ($P = 3.43 \times 10^{-5}$). We also identified <i>GLI2</i> , <i>WRN</i> , and <i>CBFB</i> eQTL that are
31	associated with global tumor mutational burden of cancer genes in ovarian cancer, glioma, and
32	esophagogastric carcinoma, respectively ($P < 3.45 \times 10^{-6}$). An <i>EPHA5</i> eQTL was associated
33	with the number of mutations in cancer genes specific to colorectal cancer, and eQTL associated
34	with expression of APC, WRN, GLI1, FANCA, and TP53 were associated with mutations in
35	genes specific to endometrial cancer ($P < 1.73 \times 10^{-5}$). Our findings provide evidence for the
36	germline-somatic associations mediated through expression of specific cancer genes and open
37	new avenues for research on the underlying biological processes, especially those related to
38	immunotherapy responses.

39 Introduction

40 Cancer is a genetic disease driven by somatic events occurring in the genome over time. 41 Identifying genes carrying driver mutations (cancer driver genes) and elucidating their roles in 42 the related signaling pathways have become primary goals in cancer genomic research because 43 of the contribution of these genetic changes to abnormal and uncontrolled cell growth and 44 transformation which drive the development of a malignant tumor (1-4). Many of these driver 45 genomic alterations have been found to be clinically actionable drug or therapeutic targets for 46 precision medicine. With the advancement of low-cost, high-throughput next-generation 47 sequencing (NGS) technologies, genomic profiling of tumors using targeted NGS panels is 48 becoming part of routine cancer care (5-8).

49 Different cancers are characterized by different patterns of somatic mutations (9,10). Even 50 patients with the same cancer may have substantial heterogeneity in the overall tumor mutational 51 burden (TMB), mutation patterns characterized by mutational signatures, or the cancer genes and 52 oncogenic signaling pathways altered (4,11-14). These heterogeneities in the somatic mutational 53 profile can lead to differential cancer progression, prognosis, and treatment response (15,16). A 54 well-known example is the predictive association of TMB and response to immunotherapy (17). 55 Mounting evidence suggests that somatic variations in tumors can have a germline genetic basis 56 (12,18-23). This germline-somatic relationship has been established at different levels, from the 57 impact of a single germline variant on somatic mutation rate of a cancer gene (e.g., rs25673 at 58 19p13.3 with *PTEN* alterations that involved in the mTOR signaling pathway) (20), to the 59 associations between germline polygenic risk scores (PRS) and somatic mutational signatures 60 (e.g., germline PRS of inflammatory bowel disease with APOBEC signatures in breast cancer) 61 (23). Emerging evidence also shows an interactive effect of germline and somatic variations on

62	clinical outcomes (24). However, the study of germline-somatic interactions is still at an early
63	stage and the mechanisms responsible for these observed associations are still largely uncovered.
64	Germline variants may affect somatic mutations through gene expression (19,22,25). In the well-
65	established example of the APOBEC mutational process, rs17000526-A allele in the APOBEC3B
66	region is associated with higher expression of this gene, which contributes to somatic
67	mutagenesis of APOBEC signatures in bladder tumor (19). Chen et al. systematically assessed
68	the impacts of expression level of putative cancer-susceptibility genes on mutational signatures
69	and TMB and identified a wide range of associations across six cancer types (25). Many
70	underlying mechanisms may co-exist, but an intuitive and interpretable hypothesis would be that
71	the germline cancer gene expression quantitative trait loci (eQTL) alter the propensity of
72	acquiring somatic mutations in those specific genes or globally through their regulatory effect on
73	gene expression. Although prior studies included gene expression information in the analysis of
74	germline-somatic interactions, this is no systematic study focusing on both the local and global
75	impact of eQTL on somatic mutations in cancer genes across multiple cancers. Many latent
76	associations and mechanisms may thus have been missed.

77 Here, we performed a pan-cancer analysis of the germline genetic impacts on both the local and 78 global tumor mutations, incorporating regulatory information of germline variants on gene expression. Specifically, we evaluated the associations between germline cancer gene eQTL and 79 80 i) somatic mutation status of those cancer genes or any hotspot mutation in those genes, ii) tumor 81 mutation counts (TMC) of all recurrently mutated cancer genes for a cancer type, and iii) TMB 82 of all targeted cancer genes from the OncoPanel sequencing platform across 11 cancer types in 83 the Dana-Farber Profile cohort. Clinical targeted sequencing cohorts are well suited for such 84 germline-somatic analysis because the tumor sequencing specifically targets those actionable

- 85 cancer drivers and the cancer patient population is usually large, unselected, and has extensive
- 86 clinical data. Our results demonstrate evidence for germline-somatic associations that are
- 87 potentially mediated through cancer gene expression and provide insights into the mechanisms of
- 88 mutagenesis in somatic cells.

89 Materials and Methods

90 Study population

The Dana-Farber Profile, initiated in 2011, is a cohort study of unselected cancer patients who 91 92 presented at the Dana-Farber Cancer Institute, Brigham and Women's Hospital, or Boston 93 Children's Hospital, received genomic profiling and consented to participate. Tumor specimens, 94 mainly formalin-fixed paraffin-embedded tissues, were retrieved from all consented patients for 95 targeted sequencing. Comprehensive clinical and pathologic data were collected along with the 96 genomic data (6,26). The study protocol was approved by the institutional review board (IRB) of 97 Dana-Farber/Partners Cancer Care Office for the Protection of Research Subjects (11-104/17-98 000). Secondary analyses of previously collected data were approved by the Dana-Farber IRB

99 (19-033/19-025).

100 Tumor targeted sequencing

101 A workflow of the full data generating and processing pipeline is present in **Fig. 1**. All collected 102 tumor samples were sequenced on OncoPanel, a targeted NGS platform designed for detecting 103 somatic variations in a panel of actionable cancer genes. There are three versions of the panel 104 targeting the exon and/or intron regions of 304, 326, and 447 genes, respectively; each patient in 105 the cohort was sequenced on one of the panels (Supplementary Table S1). All targeted genes 106 were previously identified oncogenes or tumor suppressor genes involved in cancer-related 107 signaling pathways (27). Sequencing was performed using an Illumina HiSeq 2500 with 2×100 108 paired-end reads followed by somatic mutation calling using MuTect (for single-nucleotide 109 variants) (28) and Indelocator (for indels; http://www.broadinstitute.org/cancer/cga/indelocator)

from reads aligned to the targeted genome regions with $> 50 \times$ reads ("On-target reads"). More

111 details about the tumor sequencing pipeline can be found in prior studies (6,27).

We collected somatic mutation data from the tumor sequences of 18,472 primary cancer samples spanning over 60 cancer types and subtypes. Some tumors exhibit microsatellite instability (MSI) with high mutational burden; the germline-somatic relationship for those hypermutable subtypes might be substantially different from the microsatellite stable (MSS) tumors. We thus further classified each sample as MSI or MSS using MSIDetect (29). Cancer types with > 500 samples were selected; for each selected cancer, we removed those rare subtypes with < 3 samples. The remaining 12,413 samples across 11 cancer types were included in the downstream

120 Germline imputation from tumor sequences

analysis (Supplementary Table S2).

119

121 Details of inferring common germline variants from the OncoPanel tumor sequencing data are 122 described elsewhere (26) and briefly summarized here. Tumor targeted sequencing generated 123 both high-coverage "on-target reads" aligned to the targeted regions and low-coverage "off-124 target reads" aligned to the rest of the genome (**Fig. 1**). Common germline variants with > 1%125 frequency in the European population were imputed from these tumor sequences (mainly relied 126 on off-target reads) using linkage disequilibrium (LD) information with the 1000 Genomes Phase 127 3 release as the haplotype reference panel. Imputation accuracies from several algorithms 128 designed for imputing germline variants from low coverage data were evaluated by comparing 129 the imputed allele dosage to the gold standard germline data generated from genotyping array. 130 The STITCH algorithm (30) yielded the highest overall accuracy and the resulting imputed 131 germline data were used for the downstream analysis. The imputed variants were subsequently

restricted to an imputation INFO score of greater than 0.4, which produced a mean imputation

133 correlation of 0.86 between tumor imputed and germline SNP array variants (26).

134 Genetic ancestry was inferred by projecting the imputed germline genetic data into the genetic

ancestry principal components using weights derived for European, African, and Asian

136 populations from the 1000 Genomes Project reference data (31). We further restricted our

analysis to samples with < 10% inferred non-European ancestry.

138 Identifying recurrently mutated cancer genes and hotspot mutations

139 We identified recurrently mutated cancer genes, defined as genes with $\geq 5\%$ carriers of missense 140 mutations, for each selected cancer type from the somatic data. Not all panel genes were 141 sequenced on every sample (multiple panel versions exist); we thus further excluded those 142 identified gene-cancer pairs with < 500 sequenced samples. We included additional genes that 143 were identified as highly significantly mutated or significantly mutated genes among known 144 cancer genes for each selected cancer type from the TumorPortal (http://www.tumorportal.org/) 145 (32). A total of 135 cancer genes and 342 gene-cancer pairs were identified, with the mutation 146 frequency ranging from 0.0036 to 0.73 (Fig. 2A; Supplementary Table S3). Mutation status for 147 each sample and gene is defined as whether this sample carries at least one functional mutation 148 (frame shift del, frame shift ins, frameshift, initiator codon, missense and splice region, 149 missense mutation, nonsense mutation, protein altering, splice site, start lost, stop lost, and 150 translation_start_site) in this gene and is considered to capture the "local" tumor mutation 151 (mutation in one cancer gene).

For each selected cancer type, we further identified specific mutations with \geq 5% carriers in the somatic data as hotspot mutations. Seven of the 11 cancer types harbor at least one hotspot

mutation. A total of 17 hotspot mutations and 25 mutation-cancer pairs were identified, with the
mutation frequency ranging from 0.051 to 0.33 (Fig. 2B; Supplementary Table S4). A binary
variable of the local mutation status was created to indicate whether a sample carries a specific
hotspot mutation.

158 Quantifying TMB of all panel genes and TMC of recurrently mutated cancer genes

159 TMB is defined as the total number of missense mutations per megabase based on the targeted 160 sequencing data of all panel genes (Fig. 2C). It captures the total mutations in all targeted cancer 161 genes and is considered as a refined "global" mutational burden restricting to a set of cancer-162 related genes rather than the genome-wide mutational burden. In addition to TMB, we also 163 calculated TMC for each sample, which is defined as the count of recurrently mutated cancer 164 genes (specific to each cancer type) that harbor at least one missense mutation. The number of 165 identified recurrently mutated cancer genes varies across cancer types (Fig. 2D). Compared to 166 TMB, TMC is a more refined measure of the mutational burden in likely driver genes for a 167 cancer. Moreover, by counting the genes instead of the mutations, the TMC analysis would be 168 less sensitive to hypermutable outliers.

169 Identifying eQTL from the Genotype-Tissue Expression (GTEx) Project for all selected 170 genes

We obtained the eQTL and gene expression association results in normal tissue for all selected genes from the meta-analyzed multi-tissue eQTL results using METASOFT (33) from the GTEx Analysis V8 release. We selected those genome-wide significant eQTL with $P < 5 \times 10^{-8}$ from any of the fixed effect (FE), random effect (RE), or Han and Eskin's random effect (RE2) models. Variants with minor allele frequency < 1% were further removed. A total of 28,486

176eQTL for 114 genes with imputed germline data available were included in the analysis. We177performed LD clumping with $r^2 = 0.3$ on the final list of eQTL for each gene to identify178independent loci, which was used to determine the number of effective tests in the association179analyses (34).

180 Assessing the associations of cancer gene eQTL with TMB and TMC

181 We assessed the association between each selected cancer gene eQTL and TMB of all panel 182 genes for each cancer by fitting a linear model adjusting for age, gender (if applicable), panel 183 version, and tumor purity. MSI status was also adjusted as a covariate for the models of 184 colorectal and endometrial cancer where a substantial proportion of the cases display 185 hypermutability (35,36). TMB was Winsorized to 98% within each cancer type to reduce the 186 impact of potential outliers on the association results. The associations between cancer gene 187 eQTL and TMC were evaluated for recurrently mutated cancer genes for each cancer type by 188 fitting a negative binomial model with the same covariates as the TMB models. Sensitivity 189 analysis was performed to assess the impacts of potential TMB or TMC outliers on the 190 association results by varying the Winsorization thresholds and using standardized TMB. For 191 TMC, we further evaluated the impacts of using count of missense mutations instead of count of 192 mutated genes on the germline-somatic associations.

Assessing the associations of cancer gene eQTL with recurrently mutated cancer genes and hotspot mutations

195 The local impact of each cancer gene eQTL on the risk of having somatic mutations in that gene 196 or a nearby hotspot mutation was assessed using logistic regression. These analyses further 197 adjusted for TMB along with all the covariates included in the TMB or TMC models. Meta-

10

- analysis was performed to evaluate the broad impact of a cancer gene eQTL on the mutation
- 199 status of one gene or mutation across cancers.

200 Data availability statement

- 201 The individual-level data used in this study are not publicly available due to patient privacy
- 202 requirements. Other unidentifiable data generated in this study are available within the article
- and its supplementary data files.

204 **Results**

205 Germline cancer gene eQTL influence global tumor mutations

206 We analyzed 28,486 eQTL for 114 cancer genes and assessed their associations with TMB of all cancer genes sequenced on the panel across cancers. There were 1,317 independent eQTL ($r^2 < r^2$ 207 208 0.3) after LD clumping. We identified 22 significant eQTL-TMB associations representing 3 209 independent gene-cancer pairs that passed the Bonferroni correction threshold accounting for the 210 number of effective tests ($P < 3.45 \times 10^{-6}$; Supplementary Table S5). Table 1 summarizes the 211 results for the most significant association at each locus. There exists heterogeneity in the effects 212 of these eQTL on TMB across cancers (Supplementary Table S6). Sensitivity analysis on the 213 impacts of potential outliers showed that the association of the GLI2 eQTL and TMB in ovarian 214 cancer was sensitive to the changing Winsorization threshold (Supplementary Table S7). This 215 association also became non-significant if we use standardized TMB as the outcome (beta = 216 0.26, P = 0.43) while the other two top associations remained nominally significant (beta = 217 -2.33, $P = 1.57 \times 10^{-3}$ for rs139944315 (*WRN*) and TMB in glioma; beta = -0.23, P = 0.04 for 218 rs11075646 (CBFB) and TMB in esophagogastric carcinoma).

To further investigate the relationship between the observed germline-somatic associations and gene expression, we compared our results with the association results between the identified top eQTL and expression level of the specific cancer genes in normal tissue in GTEx (**Table 1**; **Fig.** 3). The T allele of rs1530578 was associated with elevated TMB in ovarian cancer and reduced expression of *GLI2* across tissues (**Fig. 3A,D**). The largest effect of rs1530578 on *GLI2* expression was observed in ovary with beta = -0.55 and $P = 3.93 \times 10^{-5}$ (**Fig. 3A**). rs139944315 was associated with TMB in glioma and expression of *WRN* across tissues in a consistent

12

226	direction (Fig. 3B,E). While the largest effect of this variant on WRN expression was observed in
227	subcutaneous adipose tissue, there was also an association in putamen of basal ganglia with beta
228	= -0.51 for the T allele and $P = 0.05$ (Fig. 3B). Finally, we found that the C allele of rs11075646
229	was associated with decreased TMB in esophagogastric carcinoma and slightly increased
230	expression of <i>CBFB</i> across tissues (Fig. 3C,F). This variant had a nominally significant impact
231	on <i>CBFB</i> expression in both gastroesophageal junction (beta = 0.10 and $P = 0.02$, Fig. 3C) and
232	mucosa of esophagus (beta = 0.08 and $P = 0.01$) while the most significant effect was observed
233	for thyroid (Fig. 3F). None of these three top variants or variants in high LD with them have
234	been linked to cancer incidence in genome-wide association studies (GWAS) from GWAS
235	Catalog (https://www.ebi.ac.uk/gwas/home) (37).
236	We next assessed the impacts of cancer gene eQTL on TMC, which quantifies the mutational
237	burden of a set of genes that are recurrently mutated in the specific cancer. There were 145
238	significant eQTL-TMC associations after Bonferroni correction ($P < 1.73 \times 10^{-5}$; Supplementary
239	Table S8), representing six independent gene-cancer pairs (Table 1). Sensitivity analysis showed
240	that all top TMC associations were robust to a wide range of Winsorization thresholds
241	(Supplementary Table S9). Replacing count of mutated genes with count of mutations also
242	yielded similar results compared to the main analysis (Supplementary Table S10). Given that all
243	top eQTL-TMC associations were identified for colorectal and endometrial cancer, we further
244	performed a stratified analysis by MSI status. There was no substantial deviation in the effect
245	estimates for MSS or MSI subgroup from the main analysis though the subgroup results were
246	less significant, especially for MSI samples, which was likely due to the reduced sample sizes
247	(Supplementary Table S11). Finally, we compared these top eQTL-TMC associations to the
248	previous eQTL-TMB results and found that all these top germline variants were associated with

TMB in the corresponding cancers in consistent directions with TMC with nominal significance(Supplementary Table S12).

251	There exists substantial heterogeneity in the associations with gene expression level across
252	tissues for many of the top variants in the TMC associations (Fig. 4). Two of the tissue-specific
253	associations have both $P < 0.05$ and m-value > 0.8: rs10031417 and <i>EPHA5</i> expression in
254	sigmoid colon and rs7201264 and FANCA expression in uterus (Fig. 4A,E). The A allele of
255	rs10031417 was associated with lower somatic mutational burden in recurrently mutated cancer
256	genes in colorectal cancer and slightly higher expression of <i>EPHA5</i> across tissues (Fig. 4A,G);
257	this positive effect on <i>EPHA5</i> expression was larger in sigmoid colon with beta = 0.17 and $P =$
258	1.11×10^{-3} (Fig. 4A). It is worth noting that a variant that is in LD with rs10031417
259	(rs13104357, $r^2 = 0.18$) has also been reported to be associated with <i>EPHA5</i> expression in
260	colorectal tumor samples in The Cancer Genome Atlas (TCGA) (38); the direction of this
261	association in tumor was consistent with in normal tissue. rs7201264-C allele was associated
262	with both increased TMC in endometrial cancer and decreased FANCA expression across tissues
263	(Fig. 4E,K); it had a specific significant impact on <i>FANCA</i> expression in uterus (Fig. 4E ; beta =
264	-0.28 for the C allele, $P = 0.02$). rs78378222, that is in LD with the top variant identified for
265	TMC in endometrial cancer and <i>TP53</i> expression (rs17884306, $r^2 = 0.21$ with rs78378222), has
266	been previously associated with the risk of uterine fibroids and several cancers in but not the risk
267	of endometrial cancer specifically (39,40).

268 Local impacts of germline eQTL on somatic mutations in cancer genes

269 Investigation of the local impacts of eQTL for a cancer gene on somatic mutations in that gene is

also of interest as it may point to a direct and testable mechanism of how germline variations

271 modify the susceptibility to somatic events. None of the individual associations between somatic 272 mutation status for recurrently mutated genes and their eQTL passed the Bonferroni correction 273 threshold ($P < 1.73 \times 10^{-5}$). The most significant association observed was between a TSC2 274 eQTL and somatic TSC2 mutation status in endometrial cancer (beta = -1.81 for rs12918530-C 275 allele, $P = 1.56 \times 10^{-4}$; Supplementary Table S13). Looking across all cancers, there was a 276 significant ($P < 6.91 \times 10^{-5}$) association between an ATM eQTL (lead SNP: rs4753834 at 277 11q22.3) and somatic ATM mutations from a meta-analysis of 8 cancers (Fig. 5; Supplementary 278 Table S14). The G allele of rs4753834 was associated with a lower risk of having somatic mutations in ATM (beta = -0.35, $P = 3.43 \times 10^{-5}$ across cancers from FE model) and increased 279 expression of ATM in normal tissues (beta = 0.05, $P = 1.03 \times 10^{-20}$ across tissues from RE 280 281 model). This variant also had specific effects on ATM expression in many tissues related the 8 282 cancers, including mammary tissue (beta = 0.06), sigmoid colon (beta = 0.09), hypothalamus 283 (beta = 0.12), lung (beta = 0.07), and prostate (beta = 0.11), all with P < 0.05 and m-value > 0.9. 284 Moreover, variants that are in LD with rs4753834 have also been associated with ATM 285 expression in tumor samples of breast cancer (rs673281, $r^2 = 0.21$, beta = -0.08 for the T allele, $P = 1.98 \times 10^{-4}$) and glioma (rs1003623, r² = 0.21, beta = -0.11 for the T allele, $P = 4.56 \times 10^{-4}$) 286 287 (38); the directions were also consistent with those in normal tissues. We additionally tested the 288 associations of ATM eQTL and TMB or TMC of cancer genes and found that variants in LD with rs4753834 (lead SNP: rs672964, $r^2 = 0.21$ with rs4753834) were associated with TMB (beta = 289 290 -0.69 for rs672964-C, $P = 2.97 \times 10^{-5}$) and TMC (beta = -0.07 for rs672964-C, P = 0.02) in 291 non-small cell lung cancer in the consistent direction with ATM mutation status. No association 292 with cancer risk was found for rs4753834 or its tagging SNPs in GWAS Catalog.

293 We also identified nominal associations between eQTL for cancer genes identified in the global

- tumor mutation analysis with the somatic mutation status of that gene in the corresponding
- cancer. We found that rs1897693 ($r^2 = 0.42$ with rs10031417) was associated with both the
- expression of *EPHA5* in normal tissues (beta = 0.03 for the C allele, P = 0.03 across tissues from
- 297 RE model) and the somatic mutation status of *EPHA5* in colorectal cancer (beta = -0.66 for the
- 298 C allele, P = 0.01). Another variant rs55671402 was associated with FANCA expression in
- normal tissues (beta = -0.13 for the C allele, $P = 9.67 \times 10^{-13}$ across tissues from RE model; beta
- = -0.54 for the C allele, m-value = 0.98, $P = 1.35 \times 10^{-3}$ in uterus) and somatic mutations in
- 301 *FANCA* in endometrial tumors (beta = -1.23 for the C allele, $P = 8.61 \times 10^{-3}$).
- 302 We further assessed the impacts of eQTL for a cancer gene on each identified hotspot mutation
- in that gene. None of the associations passed the Bonferroni correction threshold ($P < 3.40 \times$
- 10^{-4}) with the most significant association observed for rs1867930 with p.S249C in *FGFR3* in
- bladder cancer (beta = 0.60 for the G allele, $P = 3.54 \times 10^{-3}$; Supplementary Table S15). Only
- 306 one nominally significant (P < 0.05) association from the meta-analysis across cancers was
- 307 found for rs11047823 with p.G12D in KRAS across colorectal cancer, endometrial cancer, non-
- small cell lung cancer, and pancreatic cancer (beta = 0.24 for the G allele, P = 0.01 across
- 309 cancers from the FE model), though it still did not pass the Bonferroni correction threshold for
- 310 significance ($P < 5 \times 10^{-3}$).

311 Discussion

312 In this study, we systematically evaluated the influence of germline variants that are associated 313 with cancer gene expression on somatic mutations in specific cancer genes across 11 cancer 314 types, leveraging large-scale clinical targeted panel sequencing data, germline data imputed from 315 tumor sequences, and cancer gene eQTL data from GTEx. Our analysis revealed novel 316 associations of germline eQTL for well-established cancer genes with local mutation status of a 317 single cancer gene or the global mutational burden. These findings provide the initial evidence 318 for the hypothesis that germline variants can influence local and global tumor mutations by 319 altering the expression level of specific cancer genes. The underlying molecular mechanisms of 320 the identified associations can be further investigated through functional analysis and in cancer 321 cell lines.

322 Although our findings are consistent with the putative mechanism that germline variants affect 323 somatic mutations through gene expression, there are also other possible scenarios that can yield 324 the same results (Fig. 6). First, given that there exists a causal impact of eQTL on somatic 325 mutations, we still cannot conclude that this is only mediated by the transcript abundance of the 326 specific eQTL gene. The germline eQTL may regulate the expression of other genes which 327 contribute to somatic mutagenesis, or they might be associated with somatic mutations through 328 other pathways that are not related to gene expression (Fig. 6A). Finding an eQTL signal in the 329 cancer-related tissue can provide further support that gene expression plays a role in the 330 germline-somatic relationship. Second, we are studying somatic mutations in developed tumor 331 (S') rather than in normal or precancerous tissue (S) (Fig. 6A). S' can serve as a proxy for S, 332 though it was measured after tumorigenesis and might be further influenced by other factors such 333 as the tumor microenvironment (41). Here, we are studying mutations in cancer genes that have

17

334 been identified as potential drivers for carcinogenesis. Even if some mutations in those genes 335 occurred after cancer initiation, our results could still inform us of the role of germline variants 336 in inducing somatic mutations during cancer progression. Finally, even when there is no direct 337 causal effect of germline variants on somatic mutations, we may still observe this association 338 among cancer patients. Consider the three possible scenarios in Fig. 6B given that a germline-339 somatic association was observed: germline variants may influence somatic mutation and they 340 may or may not have an effect on cancer diagnosis through other pathways; however, under the 341 situation that the germline variants only influence cancer diagnosis through other pathways and 342 there is no causal effect on somatic mutations, we may still observe this germline-somatic 343 association among cancer patients due to collider bias (Fig. 6B). We are unable to distinguish 344 between these three scenarios based on our data, but we can leverage information from other 345 sources (e.g., association results of the germline variants with cancer incidence from GWAS) to 346 weigh these possible scenarios for each identified association.

347 Most of the germline-somatic associations identified here were consistent with prior evidence, 348 and many of them may be involved in the biological mechanisms that underlie patients' response 349 to immunotherapy. Among all the identified eQTL genes, APC, ATM, CBFB, and TP53 have 350 been predicted as pan-cancer tumor suppressor genes across 33 cancer types in TCGA (1). We 351 observed that the germline variants associated with reduced expression of these tumor suppressor 352 genes were associated with increased tumor mutations, except for APC where the eQTL 353 association with gene expression was close to null across tissues (but still significant) with no 354 effect in uterus (Table 1; Fig. 3-5). The APC gene encodes the adenomatous polyposis coli 355 protein which plays an important role in the Wnt signaling pathway (42) and interacts with E-356 cadherin, which regulates cell adhesion (43). Mutations that inactivate APC lead to disruption of

357 β -catenin degradation, resulting in its translocation into the nucleus and activation of the 358 transcription of multiple genes, which triggers cancer development, including endometrial 359 carcinogenesis (44). Active β -catenin signaling has been linked to resistance to anti-PD-L1/anti-360 CTLA-4 monoclonal antibody therapy in melanoma (45). A recent study found that germline 361 pathogenic variants in APC are associated with elevated TMB (46). In our work, the minor allele 362 of the lead SNP is also associated with higher TMC of recurrently mutated cancer genes, but the 363 direction of its association with APC expression is not clear (**Table 1**; **Fig. 4**). Intuitively, we 364 would assume a variant that downregulates the expression of a tumor suppressor gene to be 365 associated with elevated risk of cancer and somatic mutational burden, but this assumption might 366 be oversimplified as the oncogenic or tumor suppressive effect of a gene on carcinogenesis and 367 on somatic mutational burden would depend on the signaling pathway that the gene involved in 368 and may vary substantially across cancer types (47). Here, the major allele of rs397768 slightly 369 downregulates APC expression across tissues, if this indicates activation of β -catenin signaling in 370 endometrial carcinogenesis, then it should be associated with resistance to immunotherapy and 371 reduced tumor mutations as we observed. However, this interpretation depends upon many 372 variable components involved in this complex biological process; further study is needed to 373 elucidate the molecular mechanisms underlying these associations.

ATM germline and somatic mutations have been linked to multiple cancers. Activated ATM
protein kinase phosphorylates a few key proteins which activates DNA damage checkpoint,
leading to its main tumor suppressive effect of cell-cycle arrest and apoptosis (48). A study of
pathogenic germline variants in cancer identified two-hits events for *ATM* where a germline
variant in *ATM* is coupled with a somatic mutation in the other copy of the gene in multiple
cancers (49). They also found that *ATM* pathogenic variant carriers had lower *ATM* expression,

19

which is in line with our finding that the minor allele of rs4753834 is associated with lower expression of *ATM* but higher risk of having somatic mutation in the gene (**Fig. 5**). Recent studies also reported that *ATM* mutations were associated with improved response to immune checkpoint blockade therapy (50,51). We observed this inverse relationship of *ATM* expression with both somatic *ATM* mutations across cancers and TMB in non-small cell lung cancer, which may support the potential role of *ATM* as a therapeutic target for promoting the response to cancer immunotherapy.

387 TP53, which encodes protein p53, is one of the most frequently mutated genes in cancer. Genetic 388 alterations in the p53 stress response pathway can affect the tumor suppressive role of TP53 and 389 promote tumorigenesis (52). Results from a recent study demonstrated evidence for the 390 interactive effects of a germline cancer risk variant, rs78378222, and somatic mutation status of 391 TP53 on cancer risk, prognosis, and drug responses (24). The C allele of rs78378222 has been 392 linked to lower expression level of wild-type TP53 in both normal tissue and tumor, which in 393 turns reduce p53 cellular activity and lead to poorer overall survival of patients. In our analysis, 394 we found that the minor allele of rs17884306, which is correlated with the C allele of 395 rs78378222, was associated with higher TMB and lower TP53 expression (Table 1; Fig. 3). One 396 study highlighted the predictive value of somatic TP53 mutations for benefit from anti–PD-397 1/PD-L1 immunotherapy in lung cancer (53). Our results may provide further insights into how 398 inherited genetic predisposition can influence patients' response to immunotherapy through its 399 effect on TP53 expression and somatic mutational burden.

400 Increased expression of *GLI2* in the hedgehog signaling pathway has been found to induce PD-

- 401 L1 expression in gastric cancer and promote tumor resistance to immunotherapy (54). We
- 402 identified a germline eQTL at 2q14.2 that upregulates *GLI2* and is associated with lower TMB in

403 ovarian cancer; nominally significant associations were also found in esophagogastric carcinoma
404 and glioma in the same directions (**Table 1**; **Fig. 3**; Supplementary Table S6). These findings
405 may shed light on the underlying mechanism of the link between TMB and response to
406 immunotherapy in these specific cancers.

407 Reduced *EPHA5* expression has been linked to lymph node metastasis, advanced TNM stage, 408 and poor survival outcome in colorectal cancer, supporting its tumor suppressive role in this 409 cancer (55). Recent work showed that having somatic EPHA5 mutations is positively associated 410 with TMB and response to immune checkpoint inhibitor therapy in lung cancer (56). We also 411 identified consistent associations of an EPHA5 eQTL at 4q13.2 with both somatic EPHA5 412 mutations and the global tumor mutations in colorectal cancer. This eQTL influences EPHA5 413 expression in colorectal cancer and normal colon tissue (**Table 1**; **Fig. 3**); the allele that was 414 associated with reduced expression was also associated with increased somatic mutations. 415 Further studies are needed to characterize the potential interactive effect of these identified 416 germline variants, EPHA5 expression, and somatic EPHA5 mutations in colorectal cancer. 417 Our study has several limitations. First, as mentioned above, we cannot easily distinguish 418 between several possible scenarios of the causal relationships that may be consistent with the 419 observed associations between germline eQTL and tumor mutations. We suggest future studies 420 to further investigate these associations in normal tissue or precancerous lesions and 421 incorporating haplotype-level information. Experimental validation is also necessary to confirm 422 the putative mechanisms through gene expression for the identified associations. Second, the use 423 of germline data imputed from off-target reads in tumor sequencing provides only a probabilistic 424 estimate of the imputed variant. Although the validation analysis of imputed common germline 425 variants against SNP array yielded high accuracy (26), it would still be important to validate

21

426	these findings using direct germline genotyping. Third, our analysis focused on somatic
427	mutations in the tumor, but we only included eQTL identified from normal tissue, which may
428	miss tumor-specific eQTL effects (19). However, using normal tissue eQTL as the genetic
429	instrument is more consistent with our hypothesis that eQTL alter gene expression in normal
430	tissue contributes to somatic mutagenesis and tumor initiation. Where available, we also cross-
431	referenced the eQTL results to those in corresponding tumor tissue and found the results had
432	consistent direction with those in normal tissue. Finally, we only focused on missense and a few
433	other functional mutations; future studies can further investigate the germline impact on somatic
434	copy number alteration or structural variation through gene regulation.
435	In conclusion, we systematically investigated the impacts of germline cancer gene eQTL on
436	somatic mutations in cancer genes across 11 cancer types. Our results indicate that germline
437	variants that regulate the expression of cancer genes also influence local and global tumor
438	mutations. These findings provide further evidence for the important role of gene expression
439	regulation in germline-somatic associations and open avenues for future research on the
440	molecular mechanisms underlying these associations that confer cancer risk and sensitize cancer
441	to immunotherapy.

442 Authors' Disclosures

443 No disclosures were reported.

444 Acknowledgements

- 445 This work was supported by National Cancer Institute grants R01CA227237 and R01CA244569
- 446 (to A. Gusev), and R01CA260352 (to P. Kraft), Phi Beta Psi Sorority, and Emerson Collective.
- 447 The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the
- 448 Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA,
- 449 NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained
- 450 from the GTEx Portal on 08/04/2021.

451

452 References 453 454 Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. 1. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 455 456 2018;173:371-85 e18 457 2. Martinez-Jimenez F, Muinos F, Sentis I, Deu-Pons J, Reves-Salazar I, Arnedo-Pac C, et al. 458 A compendium of mutational cancer driver genes. Nat Rev Cancer **2020**;20:555-72 459 3. Pon JR, Marra MA. Driver and passenger mutations in cancer. Annu Rev Pathol 460 2015;10:25-50 461 4. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic 462 Signaling Pathways in The Cancer Genome Atlas. Cell 2018;173:321-37 e10 463 Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision 5. 464 cancer therapies. Genome Med 2020;12:8 Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, et al. Institutional 465 6. 466 implementation of clinical tumor profiling on an unselected cancer population. JCI 467 Insight **2016**;1:e87062 468 7. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of 469 metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat 470 Med 2017;23:703-13 471 8. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-472 throughput detection of actionable genomic alterations in clinical tumor samples by 473 targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93 Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of 474 9. 475 somatic mutation in human cancer genomes. Nature 2007;446:153-8 476 Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in 10. 477 cancer. Nat Rev Genet **2013**;14:703-18 478 Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor Mutational Burden as 11. 479 a Predictive Biomarker in Solid Tumors. Cancer Discov 2020;10:1808-25 480 12. Consortium ITP-CAoWG. Pan-cancer analysis of whole genomes. Nature **2020**;578:82-93 481 13. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. 482 Mutational heterogeneity in cancer and the search for new cancer-associated genes. 483 Nature 2013;499:214-8 484 14. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire 485 of mutational signatures in human cancer. Nature 2020;578:94-101 486 15. Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. 487 Development of tumor mutation burden as an immunotherapy biomarker: utility for the 488 oncology clinic. Ann Oncol 2019;30:44-56 489 16. Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment 490 decisions. Cell **2012**;148:409-20 491 Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor 17. 492 Mutational Burden as an Independent Predictor of Response to Immunotherapy in 493 Diverse Cancers. Mol Cancer Ther 2017;16:2598-608

494 495	18.	Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, <i>et al.</i> Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of
496		putative APOBEC-dependent mutations in breast cancer. Nat Genet 2014 ;46:487-91
497	19.	Middlebrooks CD, Banday AR, Matsuda K, Udquim KI, Onabajo OO, Paquin A, et al.
498		Association of germline variants in the APOBEC3 region with cancer risk and enrichment
499		with APOBEC-signature mutations in tumors. Nat Genet 2016 ;48:1330-8
500	20.	Carter H, Marty R, Hofree M, Gross AM, Jensen J, Fisch KM, et al. Interaction Landscape
501		of Inherited Polymorphisms with Somatic Events in Cancer. Cancer Discov 2017 ;7:410-
502		23
503	21.	Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL, et al. The
504		context-specific role of germline pathogenicity in tumorigenesis. Nat Genet
505		2021 ;53:1577-85
506	22.	Sun X, Xue A, Qi T, Chen D, Shi D, Wu Y, et al. Tumor Mutational Burden Is Polygenic and
507		Genetically Associated with Complex Traits and Diseases. Cancer Res 2021;81:1230-9
508	23.	Liu Y, Gusev A, Heng YJ, Alexandrov LB, Kraft P. Somatic mutational profiles and
509		germline polygenic risk scores in human cancer. Genome Med 2022;14:14
510	24.	Zhang P, Kitchen-Smith I, Xiong L, Stracquadanio G, Brown K, Richter PH, et al. Germline
511		and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk,
512		Progression, and Drug Response. Cancer Res 2021;81:1667-80
513	25.	Chen Z, Wen W, Beeghly-Fadiel A, Shu XO, Diez-Obrero V, Long J, et al. Identifying
514		Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations
515		in Human Cancers. Am J Hum Genet 2019 ;105:477-92
516	26.	Gusev A, Groha S, Taraszka K, Semenov YR, Zaitlen N. Constructing germline research
517		cohorts from the discarded reads of clinical tumor sequences. Genome Med
518		2021 ;13:179
519	27.	Garcia EP, Minkovsky A, Jia Y, Ducar MD, Shivdasani P, Gong X, et al. Validation of
520		OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic
521		Variants in Cancer. Arch Pathol Lab Med 2017 ;141:751-8
522	28.	Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive
523		detection of somatic point mutations in impure and heterogeneous cancer samples. Nat
524		Biotechnol 2013 ;31:213-9
525	29.	Maruvka YE, Frazer R, Grimsby J, Van Seventer E, Gelincik O, Ibrahim M, et al. Detection
526		of tumors with microsatellite instability (MSI) using minimal sequencing of cfDNA. in
527		submission
528	30.	Davies RW, Flint J, Myers S, Mott R. Rapid genotype imputation from sequence without
529		reference panels. Nat Genet 2016 ;48:965-9
530	31.	Chen CY, Pollack S, Hunter DJ, Hirschhorn JN, Kraft P, Price AL. Improved ancestry
531		inference using weights from external reference panels. Bioinformatics 2013 ;29:1399-
532		406
533	32.	Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al.
534		Discovery and saturation analysis of cancer genes across 21 tumour types. Nature
535		2014 ;505:495-501
536	33.	Sul JH, Han B, Ye C, Choi T, Eskin E. Effectively identifying eQTLs from multiple tissues by
537		combining mixed model and meta-analytic approaches. PLoS Genet 2013;9:e1003491

538 539	34.	Sobota RS, Shriner D, Kodaman N, Goodloe R, Zheng W, Gao YT, <i>et al.</i> Addressing
540		Genet 2015 -70-136-17
540	35	Boland CR Goel A Microsatellite instability in colorectal cancer. Gastroenterology
542	55.	2010 :138:2073-87 e3
543	36	Stelloo F Jansen AMI, Osse FM, Nout RA, Creutzberg CL, Ruano D, et al. Practical
545	50.	guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol
545		2017 :28:96-102
545	37	Bunjello A MacArthur IAI Cerezo M Harris IW Havburst I Malangone C <i>et al</i> The
540	57.	NHGRI-ERI GWAS Catalog of published genome-wide association studies targeted arrays
547		and summary statistics 2019 Nucleic Acids Res 2019 :47:D1005-D12
540	20	Gong L Moi S Liu C Viang V Vo V Zhang Z <i>et al</i> DancanOTL: systematic identification of
549	50.	sic oOT s and trans oOT s in 22 cancer types. Nucleis Asids Des 2019 :46:D071 D6
	20	CIS-EQTES and trans-EQTES III 55 cancer types. Nucleic Actus Res 2016 ,40.0971-00
221	59.	Sakaue S, Kallal W, Talligawa F, Kaljalallieli J, Kulki W, Kosiliba S, et ul. A closs-
552		2021, F2:141F 24
555	40	2021 , 55.1415-24 Stacov SN Sulam D. Jonasdattir A. Massan C. Cudmundsson J. Cudhiartsson DE. at al. A
	40.	statey SN, Sulem P, Johasubelli A, Masson G, Guumunusson J, Guubjartsson DF, et ul. A
555		Const 2011 , 42, 1008, 102
550	41	Generative Control of Type Microson Strangent in Conomic Instability of
557	41.	Solugur FG, Akbulut H. The Role of Tumor Microenvironment in Genomic Instability of
558	40	Fearshood NS, Britten MD, Bodmer WF, The ABC of ABC, Hum Mel Const 2001 :10:721
559	42.	rearnineau NS, Britton MP, Bourner WF. The ABC OF APC. Hum Mor Genet 2001 ,10.721-
500	40	SS Markowska A. Dawalawska M. Lubin I. Markowska I. Signalling nathways in andomatrial
201	43.	iviarkowska A, Pawalowska W, Lubin J, Warkowska J. Signalling pathways in endometrial
502	4.4	Cancer, Contemp Oncol (Pozn) 2014 ;18:143-8 Marana Buana C. Hardissan D. Sanahaz C. Sarria D. Cassia D. Carsia Pastan C. <i>et al</i>
503	44.	Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, Garcia-Rostan G, <i>et al.</i>
504		Aphormanues of the APC/beta-catenin pathway in endometrial cancer. Oncogene
505	45	2002 ;21:7981-90 Spranger S. Bao B. Cajowski TF. Malanoma intrinsia hota catanin signalling provents
500	45.	Spranger S, Bao R, Gajewski FF. Melanoma-intrinsic beta-catenin signaling prevents
567	16	anti-tumour immunity. Nature 2015 ;523:231-5
508	46.	chatrath A, Ratan A, Dutta A. Germine variants predictive of tumor mutational burden
569	47	and immune checkpoint inhibitor efficacy. Iscience 2021 ;24:102248
570	47.	Jonsson P, Bandiamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, et al.
5/1	40	Tumour lineage snapes BRCA-mediated prenotypes. Nature 2019 ;571:576-9
572	48.	Cremona CA, Benrens A. ATM signalling and cancer. Oncogene 2014 ;33:3351-60
5/3	49.	Huang KL, Mashi KJ, Wu Y, Ritter DI, Wang J, On C, et al. Pathogenic Germine Variants in
574	-0	10,389 Adult Cancers. Cell 2018 ;1/3:355-70 e14
575	50.	Hu M, Zhou M, Bao X, Pan D, Jiao M, Liu X, <i>et al</i> . ATM inhibition enhances cancer
576		Immunotherapy by promoting mtDNA leakage and cGAS/STING activation. J Clin Invest
5//	- 4	ZUZI;131
578	51.	Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, et al. Inhibition of ATM
579		Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint
580		Blockade Therapy. Cancer Res 2019 ;79:3940-51

- 581 52. Stracquadanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, *et al.* The
 582 importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat Rev
 583 Cancer **2016**;16:251-65
- 53. Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, *et al.* Potential Predictive Value of TP53
 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung
 Adenocarcinoma. Clin Cancer Res **2017**;23:3012-24
- 587 54. Chakrabarti J, Holokai L, Syu L, Steele NG, Chang J, Wang J, et al. Hedgehog signaling
 induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget
 2018;9:37439-57
- 590 55. Gu S, Feng J, Jin Q, Wang W, Zhang S. Reduced expression of EphA5 is associated with
 lymph node metastasis, advanced TNM stage, and poor prognosis in colorectal
 carcinoma. Histol Histopathol 2017;32:491-7
- 59356.Huang W, Lin A, Luo P, Liu Y, Xu W, Zhu W, et al. EPHA5 mutation predicts the durable594clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.
- 595 Cancer Gene Ther **2021**;28:864-74

Table 1. Significant associations between cancer gene eQTL and global tumor mutations

	eQTL						Association results with TMB or TMC			Association results with gene expression from GTEx ^a					
Cancer type	Region	Lead SNP	Pos ^b	Effect allele	Other allele	EAF	Beta	SE	P value	Gene	Beta (FE)	P value (FE)	Beta (RE)	P value (RE)	P value (RE2)
TMB of all cancer genes on OncoPanel															
Ovarian Cancer	2q14.2	rs1530578	121702128	Т	С	0.01	17.61	3.02	1.26E-08	GLI2	-0.11	2.41E-16	-0.11	2.00E-10	1.33E-16
Glioma	8p12	rs139944315	30332577	Т	А	0.99	-16.36	2.65	1.21E-09	WRN	-0.30	6.35E-44	-0.28	4.16E-20	6.79E-45
Esophagogastric Carcinoma	16q22.1	rs11075646	66969176	С	G	0.90	-2.57	0.53	1.48E-06	CBFB	0.05	2.06E-12	0.05	1.34E-08	3.03E-12
TMC of recurrently mutated cancer g	enes														
Colorectal Cancer	4q13.2	rs10031417	66700879	А	G	0.55	-0.18	0.04	2.04E-06	EPHA5	0.03	5.63E-05	0.03	4.12E-02	6.36E-13
Endometrial Cancer	5q22.2	rs397768	112181576	G	А	0.38	0.24	0.05	1.43E-05	APC	0.01	7.91E-02	0.00	7.36E-01	3.77E-10
Endometrial Cancer	8p12	rs11782945	31082006	G	А	0.41	0.58	0.12	4.95E-07	WRN	0.06	1.06E-26	0.06	4.95E-21	3.14E-26
Endometrial Cancer	12q13.3	rs73115907	57754701	G	А	0.76	-0.31	0.06	4.61E-07	GLI1	-0.02	2.75E-03	-0.02	1.31E-01	2.99E-08
Endometrial Cancer	16q24.3	rs7201264	90036122	С	G	0.20	0.41	0.07	1.10E-08	FANCA	-0.07	4.70E-18	-0.09	1.32E-07	8.17E-41
Endometrial Cancer	17p13.1	rs17884306	7572101	С	Т	0.94	-0.60	0.13	4.36E-06	<i>TP53</i>	0.09	2.41E-16	0.08	4.45E-12	8.15E-16

^a Meta-analysis results of the associations between the eQTL and normalized gene expression levels across 49 tissues

^b Position based on GRCh37/hg19

Figures

Figure 1. A workflow of the germline and somatic data generation pipeline in the Profile cohort. Tumor samples were collected from all consented patients in the Profile cohort, followed by targeted sequencing using OncoPanel. Somatic data were generated from on-target reads from the tumor sequences. Germline data were imputed using both the off-target and on-target reads generated from tumor sequencing. Four measures of the local and global tumor mutations: i) Mutation status of recurrently mutated cancer genes, ii) Mutation status of hotspot mutations, iii) TMC of recurrently mutated cancer genes, and iv) TMB of all panel genes were generated for all selected primary cancer samples across 11 cancer types from somatic data. Germline eQTL were identified from GTEx for all identified genes, followed by germline allele dosage extraction from the germline imputed data.

Figure 2. Local and global tumor mutations of 11 cancer types. A, Mutation frequency and sample size of the identified recurrently mutated cancer genes for each cancer type. A total of 135 genes were selected for 11 cancer types (Supplementary Table S3); only genes that are recurrently mutated in \geq 5 cancer types are shown on this figure. B, Mutation frequency and sample size of the identified hotspot mutations for each cancer type. There are 17 hotspot mutations in 10 genes for 7 cancer types. C, Distribution of TMB of all panel genes across cancers with sample sizes. D, Distribution of TMC of recurrently mutated cancer genes across cancers. Each dot represents a sample. The red horizontal line represents the median of TMC for each cancer type. The total number of recurrently mutated cancer genes selected for each cancer is listed on the top of the figure.

Figure 3. Associations of eQTL with TMB of all panel genes and gene expression across

tissues. A-C, All selected eQTL for genes identified from the top eQTL-TMB associations are shown. Association results $(-\log_{10}(P))$ for eQTL and TMB are from linear models adjusting for age, gender (if applicable), tumor purity, and panel version. Association results (m-value, the posterior probability that an effect exists in a tissue) for eQTL and gene expression in the "matching tissue" are from GTEx; matching tissue was selected as the tissue with the largest mvalue among all relevant tissues for the corresponding cancer type. Each dot represents a variant; variants that are significantly associated with both TMB and gene expression (in any metaanalysis model) are in red with the top variant marked as yellow diamond. RSID, effect allele, effect size, P value, and m-value for the top variant are annotated on the plots. The horizontal red dashed lines denote the significant threshold for TMB associations ($P = 3.45 \times 10^{-6}$) and "has an effect" threshold for gene expression associations in the matching tissue (m-value = 0.9). **D-F**, Association results of the top variants with expression level of the eQTL genes identified from the top eQTL-TMB associations by tissue from GTEx. The $-\log_{10}(P)$ are from single-tissue eQTL analysis. Each dot represents a tissue with the matching tissue for the specific cancer marked as yellow triangle. Meta-analysis results across tissues from FE and RE models are provided on the plots. See Fig. 5 for tissue annotations.

Figure 4. Associations of eQTL with TMC of recurrently mutated cancer genes and gene expression across tissues. A-F, All selected eQTL for genes identified from the top eQTL-TMC associations are shown. Association results $(-\log_{10}(P))$ for eQTL and TMC are from negative binomial models adjusting for age, gender (if applicable), tumor purity, panel version, and MSI status. Association results (m-value, the posterior probability that an effect exists in a tissue) for eQTL and gene expression in the "matching tissue" are from GTEx; matching tissue was selected as the tissue with the largest m-value among all relevant tissues for the corresponding cancer type. Each dot represents a variant; variants that are significantly associated with both TMC and gene expression (in any meta-analysis model) are in red with the top variant marked as yellow diamond. RSID, effect allele, effect size, *P* value, and m-value for the top variants are annotated on the plots. The horizontal red dashed lines denote the significant threshold for TMC associations ($P = 1.73 \times 10^{-5}$) and "has an effect" threshold for gene expression associations in the matching tissue (m-value = 0.9). **G-L**, Association results of the top variants with the expression level of the eQTL genes identified from the top eQTL-TMC associations by tissue from GTEx. The $-\log_{10}(P)$ are from single-tissue eQTL analysis. Each dot represents a tissue with the matching tissue for the specific cancer marked as yellow triangle. Meta-analysis results across tissues from FE and RE models are provided on the plots. See Fig. 5 for tissue annotations.

Figure 5. rs4753834 is associated with both ATM expression and somatic ATM mutations.

A, Associations between rs4753834 and risk of having somatic mutations in *ATM* across 8 cancers. The odds ratio is associated with the G allele of rs4753834. Meta-analysis results from the fixed-effect model are shown. **B**, Sample sizes and mutation frequencies of the 8 cancer types. Note that these numbers are based on samples included in the final models. **C**, Association results of rs4753834 and *ATM* expression by tissue from GTEx. The $-\log_{10}(P)$ are from single-tissue eQTL analysis. m-value is the posterior probability that an effect exists in a tissue. Results from the FE and RE meta-analysis across tissues are also shown on the plot.

Figure 6. Hypothetical relationships between germline variants, cancer gene expression, somatic mutations, and cancer diagnosis. A, Complete relationships between germline eQTL, environmental factors (E), expression level of cancer genes in normal tissue (transcript

abundance, T), somatic mutations in cancer genes in normal tissue before tumor development (S), cancer diagnosis (D), and somatic mutations in cancer genes in tumor after cancer diagnosis (S'). Our hypothesis is that germline eQTL regulate the expression of cancer genes; the transcript abundance of those cancer genes modifies the propensity of acquiring somatic mutations in those genes; having somatic mutations in those cancer genes is associated with an increased risk of cancer (the path shown by red arrows). Here, we are testing the associations between the eQTL and S', which can serve as a proxy for S, among cancer patients (conditioning on D). **B**, Three possible relationships between germline variants (G), somatic mutations in normal tissue before tumor development (S), cancer diagnosis (D), and somatic mutations in tumor after cancer diagnosis (S') given that an association between G and S' is observed. Blue arrows on the graphs show the paths from G to S' through S given that only cancer patients are included in the study (conditioning on D).











8.8

90000000

p = 4.7e-18i

0.8



 $\begin{array}{c} \mathsf{A} \\ \mathsf{eQTL} \\ \bullet \\ \mathsf{eQTL} \\ \bullet \\ \mathsf{D} \\ \mathsf{D} \\ \mathsf{D} \\ \mathsf{D} \\ \mathsf{C} \\ \mathsf{$







G induces S and cancer

G induces S

No effect of G on S